BioCardia spikes after Medicare coverage for cell therapy trial [Seeking Alpha]
BioCardia, Inc. (BCDA)
US:NASDAQ Investor Relations:
biocardia.com/investors/press-releases/id/1037?pressreleaseid=41
Company Research
Source: Seeking Alpha
Accordingly, the treatment centers taking part in the trial will be reimbursed for the study procedure and products. The confirmatory trial known as CardiAMP Heart Failure II is designed to evaluate CardiAMP, an autologous cell therapy, in patients with ischemic heart failure. The CMS decision is backed by data from the company's CardiAMP Heart Failure trial, which indicated a 37% risk reduction for all-cause heart death in patients with advanced chronic heart failure, according to a March readout. CardiAMP Heart Failure II is expected to enroll up to 250 patients in up to 40 trial centers. “We are pleased that CMS has provided coverage support for the confirmatory CardiAMP Heart Failure II study,” BioCardia ( BCDA CEO Peter Altman remarked. Recommended For You Recommended For You About BCDA Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
BCDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCDA alerts
High impacting BioCardia, Inc. news events
Weekly update
A roundup of the hottest topics
BCDA
News
- BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024GlobeNewswire
- BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important OutcomesGlobeNewswire
- BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort [Yahoo! Finance]Yahoo! Finance
- BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In CohortGlobeNewswire
- BioCardia, Inc. (NASDAQ:BCDA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
BCDA
Earnings
- 11/8/23 - In-Line
BCDA
Sec Filings
- 5/1/24 - Form 8-K
- 4/19/24 - Form 4
- 4/15/24 - Form DEF
- BCDA's page on the SEC website